天新药业: 信息披露管理制度

Core Points - The document outlines the information disclosure management system of Jiangxi Tianxin Pharmaceutical Co., Ltd, aiming to ensure the authenticity, accuracy, and completeness of disclosed information to protect investors' rights [1][2][3] Group 1: General Principles - The system applies to all individuals and entities that may significantly impact the trading price of the company's securities [2] - Information disclosure must be timely, meaning within two trading days from the triggering event [2] - The board of directors is responsible for establishing and ensuring the effective implementation of the disclosure system [2][3] Group 2: Disclosure Obligations - Information must be disclosed simultaneously to all investors without prior leaks to any individual or entity [2][3] - The company must ensure that all shareholders have equal access to disclosed information [6] - The board secretary is responsible for coordinating the execution of the information disclosure management system [3][5] Group 3: Reporting Procedures - Regular reports must be prepared and disclosed within specified timeframes, including annual, semi-annual, and quarterly reports [8][10] - The company must report any inability to disclose regular reports on time, including reasons and proposed solutions [10][12] - Major events that could significantly affect the trading price of the company's securities must be disclosed immediately [36][39] Group 4: Responsibilities and Accountability - The board of directors and senior management must ensure the authenticity and completeness of the disclosed information [52][54] - The audit committee is responsible for reviewing the financial information in regular reports [25] - Violations of the disclosure system may lead to penalties and legal responsibilities for the individuals involved [30][82]